公开(公告)号：WO2022251948A1

公开(公告)日：2022-12-08

申请号：PCT/CA2022/050334

申请日：2022-03-08

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LIU, Mingyao ,  KESHAVJEE, Shafique ,  CYPEL, Marcelo

IPC: A01N1/02

Abstract: Provided is a lung preservation composition comprising a non-carbonic buffered nutrient media, preferably a phosphate buffered nutrient media, and a dextran, optionally Dextran 40 and and optionally prostaglandin E1 (PGE1), and optionally at least one of alpha 1 antitrypsin (A1AT), an impermeant, optionally raffinose, an antioxidant, optionally glutathione, and necrostatin-1. Also described is a method of preserving a lung prior to and/or during transplant using said lung preservation composition, and kits comprising one or more components of the lung preservation composition.

公开(公告)号：WO2020118452A1

公开(公告)日：2020-06-18

申请号：PCT/CA2019/051813

申请日：2019-12-13

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KESHAVJEE, Shafique ,  LIU, Mingyao ,  CYPEL, Marcelo ,  SAGE, Andrew

IPC: G01N33/48 ,  G01N33/53 ,  G01N33/543 ,  G06F16/90 ,  G06N20/00

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10 and IL-1β optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers selected from IL-8, IL-6, IL-10 and IL-1β and optionally one or both of sTNFR1 and sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the at least three biomarkers in the perfusate sample with control EVLP data or a cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the one or more parameter values related to a level of the at least three biomarkers in combination, as part of an algebraic calculation or model of outcome/risk.

公开(公告)号：WO2021198865A1

公开(公告)日：2021-10-07

申请号：PCT/IB2021/052546

申请日：2021-03-26

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LIU, Mingyao ,  KESHAVJEE, Shafique

IPC: A01N1/02 ,  A61M1/14

Abstract: An organ perfusion solution includes a colloid component, a salt mixture, a buffer system, and a glutamine compound in a physiologically acceptable medium.

公开(公告)号：WO2020034043A1

公开(公告)日：2020-02-20

申请号：PCT/CA2019/051121

申请日：2019-08-16

Applicant: THE UNIVERSITY OF BRITISH COLUMBIA ,  UNIVERSITY HEALTH NETWORK

Inventor： CYPEL, Marcelo ,  WANG, Aizhou ,  KESHAVJEE, Shafique ,  WITHERS, Stephen G. ,  RAHFELD, Peter ,  KIZHAKKEDATHU, Jayachandran

IPC: A01N1/02 ,  A61K35/12 ,  C12N9/24 ,  C12P19/00

Abstract: Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods, uses, associated therewith. In particular, the perfusion fluids comprise two enzymes, GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore, the compositions described herein were found to have activity at temperatures and pH levels suitable for cell viability.

公开(公告)号：WO2018184100A1

公开(公告)日：2018-10-11

申请号：PCT/CA2018/050400

申请日：2018-03-29

Applicant: UNIVERSITY HEALTH NETWORK ,  BAGNATO, Vanderlei, Salvador

Inventor： BAGNATO, Vanderlei, Salvador ,  CYPEL, Marcelo ,  KESHAVJEE, Shafique ,  WADDELL, Thomas, Kenneth ,  GALASSO, Marcos, Theophilo

IPC: A61L2/08 ,  A61L2/10 ,  B01L3/00

Abstract: Disclosed are apparatuses and methods for irradiating a perfusate. The apparatus includes a tank which defines a first chamber. A separator is located inside the first chamber. The separator defines a second chamber. The first chamber and the second chamber are concentric and have substantially annular cross sections, each having at least one diameter and a substantially common longitudinal axis. A perfusate is introduced into the first chamber by an inlet. A UV radiation-emitting device is disposed inside the second chamber for providing irradiation to the perfusate. Irradiated perfusate is removed from the tank by an outlet. Other apparatuses and systems are described and methods for inactivating micro organisms by performing EVP and irradiating the perfusate.

公开(公告)号：WO2023044583A1

公开(公告)日：2023-03-30

申请号：PCT/CA2022/051424

申请日：2022-09-26

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KESHAVJEE, Shafique ,  SAGE, Andrew ,  CYPEL, Marcelo ,  MARTINU, Tereza

IPC: G01N33/50 ,  G01N33/52

Abstract: Methods, kits and devices for assessing bile acid in a donor lung and/or a transplant recipient are described. The methods involve obtaining from the donor lung or transplant recipient a bronchial wash sample, optionally a bronchoalveolar lavage (BAL) sample or a large airway bronchial wash (LABW) sample; measuring in the bronchial wash sample the level of bile acid and optionally one or more inflammation markers, comparing biomarker levels with a control or cut-off level, wherein a differential biomarker level is indicative of an outcome of the donor lung or transplant recipient, including risk of aspiration, suitability of the donor lung, or risk of a particular outcome in the transplant recipient.

公开(公告)号：WO2021179096A

公开(公告)日：2021-09-16

申请号：PCT/CA2021/050343

申请日：2021-03-15

Applicant: UNIVERSITY HEALTH NETWORK [CA]/[CA]

Inventor： SAGE, Andrew ,  VALERO, Jerome ,  DEL SORBO, Lorenzo ,  CYPEL, Marcelo ,  WANG, Bo ,  KESHAVJEE, Shafique

IPC: G01N33/48 ,  G01N33/53 ,  G01N33/543 ,  G16H50/30

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk in a patient with a respiratory illness, the method comprising: a. obtaining a sample obtained from the patient; b. quantitatively measuring in the sample a polypeptide level of one or more biomarkers selected from: IL-6, CXCL8, IL-10, IL-1RA, IL-2, IL-4, IL-7, IL-9, IL-13, IL-17, IFN-g, IP-10, MCP-1, G-CSF, GM-CSF, FGF-basic, SCGF-β, GRO-α, MIP1-α, MIP1-β, CK-18, PDGF-bb, caspase 3, HMGB-1, TNF α, VEGF, sTNFR1 and sTREM1; and c. i) comparing the level of the one or more biomarkers in the sample with a control or cut-off level, wherein the differential level is indicative of patient outcome risk; or ii) using the polypeptide level of several of the biomarkers in combination, as inputs for an algebraic calculation or machine learning model of patient outcome risk.

公开(公告)号：WO2015154170A1

公开(公告)日：2015-10-15

申请号：PCT/CA2015/000240

申请日：2015-04-10

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HARRISON, Daniel Gavin ,  FROST, Geoffrey Samuel ,  WADDELL, Thomas Kenneth ,  WYVILL, Laura Ann ,  CRACAUER, Raymond Francis ,  KESHAVJEE, Shafique ,  CYPEL, Marcelo ,  YANG, Randy

IPC: A61B17/34 ,  A61M39/02

CPC classification number: A61M39/0247 ,  A01N1/0247 ,  A61M2039/0258 ,  A61M2039/0261 ,  A61M2039/0264 ,  A61M2039/0273 ,  A61M2039/0276

Abstract: A cannula for connecting a medical device to a biological system is taught. The cannula includes a tissue engagement portion, preferably in the form of an annulus, to which a vacuum is applied through the cannula to attract and hold tissue of the biological system in an initial connection while an affixment device is applied to complete the connection. In addition to a working fluid conduit, comprising a main port, a working fluid passage and a working fluid port, and a port to apply the vacuum, the cannula can include a sensor port to allow sensing pressure or other characteristics of the working fluid at a point closely adjacent to the connection between the cannula and the biological system.

Abstract translation: 教导了用于将医疗装置连接到生物系统的套管。 套管包括优选为环形的组织接合部分，当施加固定装置以完成连接时，真空通过套管施加真空以在初始连接中吸引和保持生物系统的组织。 除了包括主端口，工作流体通道和工作流体端口以及施加真空的端口的工作流体导管之外，套管还可以包括传感器端口，以允许感测工作流体的压力或其它特性 与插管和生物系统之间的连接紧密相邻的点。

公开(公告)号：WO2022226632A1

公开(公告)日：2022-11-03

申请号：PCT/CA2022/050625

申请日：2022-04-22

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KESHAVJEE, Shafique ,  CYPEL, Marcelo ,  LIU, Mingyao ,  JUVET, Stephen ,  MESAKI, Kumi

IPC: C12N15/85 ,  A61K31/7105 ,  A61K35/12 ,  A61K38/46 ,  A61P29/00 ,  A61P37/06 ,  C12N5/10 ,  C12N5/071 ,  C12N15/09 ,  C12N15/12 ,  C12N15/19 ,  C12N15/113

Abstract: The present disclosure relates generally to epigenetically and genetically modified organs and tissues and methods of producing same. In particular, the present disclosure is directed to organs and tissues that have been epigenetically and/or genetically modified at one or multiple loci to control inflammation-regulating or immune-regulating gene expression and thereby improve the condition of the organs and tissues.

公开(公告)号：WO2022087741A1

公开(公告)日：2022-05-05

申请号：PCT/CA2021/051526

申请日：2021-10-28

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： MURPHY, Kieran ,  VUCEVIC, Diana ,  KESHAVJEE, Shafique

IPC: G01N1/28 ,  A01N1/02 ,  C12N15/10 ,  C12Q1/6806 ,  C12N1/04

Abstract: Provided is a fixative composition comprising from at least 5 percent to 50 percent syrup, optionally honey, preferably, at least 10 syrup, and dextran and optionally coconut oil, optionally from at least 10g/L to about 60 g/L of dextran, preferably about 50 g/L and/or from at least 0.5 percent to 15 percent coconut oil, preferably at least 1 percent coconut oil, methods of making the solution, methods of using the solution, for example methods for preserving a biological sample in said solution, and containers and kits comprising the solution.